Two vs three doses of human papillomavirus vaccine: New policy for the second decade of the vaccination program

JAMA - Journal of the American Medical Association

Volumn 316, Issue 22, 2016, Pages 2370-2372

  Markowitz, Lauri E ^a   Meites, Elissa ^a   Unger, Elizabeth R ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HEALTH CARE POLICY; HUMAN; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; UNITED STATES; VACCINATION; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; ADVISORY COMMITTEE; AGE; BLOOD; CHILD; DRUG APPROVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; IMMUNIZATION; IMMUNOLOGY; MALE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; AGE FACTORS; ANTIBODIES, VIRAL; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; DRUG APPROVAL; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MALE; PAPILLOMAVIRUS VACCINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 85007564407     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.16393     Document Type: Editorial

References (22)

1. Markowitz LE, Dunne EF, SaraiyaM, et al; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30.
2. DroletM, Bénard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-580.
3. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5): F123-F138.
4. Kreimer AR, Rodriguez AC, Hildesheim A, et al; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19): 1444-1451.
5. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309(17): 1793-1802.
6. Puthanakit T, Huang LM, Chiu CH, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years vs a 3-dose regimen in women aged 15-25 years. J Infect Dis. 2016;214(4):525-536.
7. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016; 12(1):20-29.
8. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43): 465-491.
9. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. doi:10.1001/jama.2016.17615
10. US Food and Drug Administration. Highlights of prescribing information: Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf. Accessed November 10, 2016.
11. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723.
12. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: A population-based analysis. Br J Cancer. 2016;114 (11):1261-1264.
13. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597-603.
14. Brotherton JM, MalloyM, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res. 2015;1:59-73.
15. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-832.
16. Chesson HW, Ekwueme DU, SaraiyaM, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011; 29(46):8443-8450.
17. Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: A cost-effectiveness analysis. J Infect Dis. 2016;214(5):685-688.
18. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27(41):5612-5619.
19. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-2162.
20. Kjaer SK, Nygard M, Dillner J, et al. Long-term effectiveness and safety of GARDASIL™ in the Nordic countries. Presented at: Eurogin 2015 Conference; February 4-7, 2015; Seville, Spain. Abstract OC 6-1.
21. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850-858.
22. Gee J,Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406-1417.